medicine-technology-1/keryx-biopharmaceuticals--inc--announces-third-quarter-2009-financial-results-6104-3/;msg18067;topicseen
| We're sorry, that page (http://www.bio-medicine.org/medicine-technology-1/keryx-biopharmaceuticals--inc--announces-third-quarter-2009-financial-results-6104-3/;msg18067;topicseen) was not found. Search medicine technology 1 keryx biopharmaceuticals inc announces third quarter 2009 financial results 6104 3 ;msg18067;topicseen at Google Search medicine technology 1 keryx biopharmaceuticals inc announces third quarter 2009 financial results 6104 3 ;msg18067;topicseen at Yahoo Search medicine technology 1 keryx biopharmaceuticals inc announces third quarter 2009 financial results 6104 3 ;msg18067;topicseen at Msn |
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3
[0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head[0] Dendreon Appoints Hans Bishop as Chief Operating Officer[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years[0] New silicon-germanium nanowires could lead to smaller, more powerful electronic devices
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Neurocrine Biosciences Amends Corporate Headquarters Lease 14319 1Express Scripts Announces Third Quarter 2009 Earnings Conference Call 5168 1Express Scripts Announces Third Quarter 2009 Earnings Conference Call 5168 2East African cichlid fish offer new understanding of genetic basis of sex determination 10229 1East African cichlid fish offer new understanding of genetic basis of sex determination 10229 2
[0] Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program[0] Hand Surgeons Take Ethics into Their Own Hands[0] Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
| Copyright © 2003-2007 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |